Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Published:2020-04 Issue:4 Volume:19 Page:298-306
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Tahara Masayuki,Oeda Tomoko,Okada Kazumasa,Kiriyama Takao,Ochi Kazuhide,Maruyama Hirofumi,Fukaura Hikoaki,Nomura Kyoichi,Shimizu Yuko,Mori Masahiro,Nakashima Ichiro,Misu Tatsuro,Umemura Atsushi,Yamamoto Kenji,Sawada Hideyuki

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference31 articles.

1. The clinical course of neuromyelitis optica (Devic's syndrome);Wingerchuk;Neurology,1999

2. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders;Wingerchuk;Neurology,2015

3. Failure of natalizumab to prevent relapses in neuromyelitis optica;Kleiter;Arch Neurol,2012

4. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum;Shimizu;Neurology,2010

5. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder;Pittock;N Engl J Med,2019

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan;Multiple Sclerosis and Related Disorders;2024-10

2. NMOSD and MOGAD: an evolving disease spectrum;Nature Reviews Neurology;2024-09-13

3. Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study;Journal of Neurology, Neurosurgery & Psychiatry;2024-09-04

4. Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM);Multiple Sclerosis and Related Disorders;2024-09

5. Unusual demyelinating disease in a patient with HIV infection;Journal of NeuroVirology;2024-08-18